Royal Philips (NYSE:PHG) said today that its board of directors is backing the re-appointment of Frans van Houten as its president and CEO and Abhijit Bhattacharya as chief financial officer and board member. CEO van Houten has been at the head of Philips since 2011, while Bhattacharya joined the company in 2015, Amsterdam-based Philips said. During […]
Harvard Bioscience Inc.
Harvard Bioscience lowers guidance in Q3 earnings
Shares in Harvard Biosciences (NSDQ:HBIO) fell today after the medtech company met expectations on Wall Street with its third quarter earnings results, but dropped its guidance for the full year. The Holliston, Mass.-based company posted losses of $256,000, or 1¢ per share, on sales of $28.6 million for the three months ended September 30, seeing […]
HART CEO David Green on the transformative potential for regenerative medicine
Layoffs: Harvard Bioscience cuts 13% of workforce
Massachusetts medtech company Harvard Bioscience’s (NSDQ:HBIO) announced today that it plans to cut about 13% of its global workforce, expecting to reap about $2 million in annual savings.
World’s 1st regenerated trachea recipient faring well at 5 years
Harvard Bioscience ditches IPO in favor of a spin-out
Harvard Bioscience’s (NSDQ:HBIO) regenerative therapies business will begin operating as an independent, publicly traded company at the start of next month, ditching original plans to launch an initial public offering.
Insulet appoints 1st medical director | Personnel Moves
Insulet (NSDQ:PODD) said it named Dr. Howard Zisser, the former clinical director of the Sansum Diabetes Research Institute, as its 1st medical director.
Considered a leader in diabetes research, Zisser will be involved with a variety of clinical research projects and serve as a medical liaison between Insulet and government leaders, the FDA, and healthcare organizations, Bedford, Mass.-based Insulet said.
Harvard Bio names new CEO amid regenerative therapies spinout
Massachusetts scientific instrument maker Harvard Bioscience named Jeffrey Duchemin its new CEO, who took over the company in the midst of the spinout of its regenerative therapies unit.
ConforMIS lures Zimmer ops director to be its new operations SVP | Personnel Moves
ConforMIS lured Zimmer’s dental business operations director, Matthew Scott, away to be its new chief operating officer as it looks to scale up its customized knee implant business.
The Bedford, Mass.-based medical device company said Scott bring’s a decade’s worth of ops experience from his tenure at Zimmer. ConforMIS makes knee replacement implants and instrumentation that are custom-fit to patients’ morphology.
Boston Scientific’s Irish ops pulled down $1.4B last year | Wall Street Beat
Boston Scientific (NYSE:BSX) posted pre-tax profits of $1.4 billion from its Irish unit and other foreign subsidiaries last year, according to the Irish Times.
Marlborough, Mass.-based medical device company Boston Scientific is 1 of the Emerald Isle’s largest employers, with a 4,500-employee workforce there.
First U.S. patient to get stem cell trachea transplant dies
Christopher Lyles, the 1st U.S. patient and the 2nd worldwide to receive a stem cell trachea transplant, died this month of unknown causes.
Lyles received an experimental trachea grown from his own stem cells and cultivated in a bioreactor made by Harvard Bioscience (NSDQ:HBIO) in November 2011.
